RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Theravance Biopharma Stock

Theravance Biopharma P/E 2024

Theravance Biopharma P/E

-9.32

Ticker

TBPH

ISIN

KYG8807B1068

WKN

A1137V

As of Sep 27, 2024, Theravance Biopharma's P/E ratio was -9.32, a -16.41% change from the -11.15 P/E ratio recorded in the previous year.

The Theravance Biopharma P/E history

Theravance Biopharma Aktienanalyse

What does Theravance Biopharma do?

Theravance Biopharma Inc is a company that was founded in 2014 and is headquartered in South San Francisco, California. The company is a spin-off of Theravance Inc, which was founded in 1996 and specialized in the development of drugs for respiratory diseases and infections. The business model of Theravance Biopharma is to develop and market innovative drugs for severe respiratory diseases, infections, and immunological disorders. The company works closely with its partners and scientific network to discover, develop, and market new drugs. Theravance Biopharma is divided into several business units, including Theravance Biopharma R&D, which focuses on drug discovery and development, and Theravance Biopharma Commercialization, which focuses on marketing Theravance's products. The company has developed and launched a number of products, including the branded products Vibativ and Velusetrag. Vibativ is an antibiotic used to treat severe lung infections and other infections, while Velusetrag was developed for the treatment of chronic constipation in patients with gastrointestinal disorders such as irritable bowel syndrome. The company also has a broad pipeline of products in various stages of development. This includes drugs for the treatment of asthma and chronic obstructive pulmonary disease (COPD), autoimmune and inflammatory diseases such as Crohn's disease and ulcerative colitis, as well as infections such as MRSA and pneumococcal. Theravance Biopharma has also formed a strong partnership with GSK (GlaxoSmithKline), one of the world's leading pharmaceutical companies. The two companies are working together to develop drugs to help patients with severe respiratory diseases, infections, and immune disorders. In summary, Theravance Biopharma is an innovative company that focuses on the discovery, development, and commercialization of drugs for the treatment of severe respiratory diseases, infections, and immune disorders. The company has a strong pipeline of products in various stages of development and a strong partnership with GSK to continue providing innovative solutions for patients with severe illnesses. Theravance Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Theravance Biopharma's P/E Ratio

The Price to Earnings (P/E) Ratio of Theravance Biopharma is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Theravance Biopharma's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Theravance Biopharma is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Theravance Biopharma’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Theravance Biopharma stock

What is the price-to-earnings ratio of Theravance Biopharma?

The price-earnings ratio of Theravance Biopharma is currently -9.32.

How has the price-earnings ratio of Theravance Biopharma changed compared to last year?

The price-to-earnings ratio of Theravance Biopharma has increased by -16.41% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Theravance Biopharma high compared to other companies?

Yes, the price-to-earnings ratio of Theravance Biopharma is high compared to other companies.

How does an increase in the price-earnings ratio of Theravance Biopharma affect the company?

An increase in the price-earnings ratio of Theravance Biopharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Theravance Biopharma affect the company?

A decrease in the price-earnings ratio of Theravance Biopharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Theravance Biopharma?

Some factors that influence the price-earnings ratio of Theravance Biopharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Theravance Biopharma pay?

Over the past 12 months, Theravance Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Theravance Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Theravance Biopharma?

The current dividend yield of Theravance Biopharma is .

When does Theravance Biopharma pay dividends?

Theravance Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Theravance Biopharma?

Theravance Biopharma paid dividends every year for the past 0 years.

What is the dividend of Theravance Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Theravance Biopharma located?

Theravance Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Theravance Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Theravance Biopharma from 9/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Theravance Biopharma pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Theravance Biopharma in the year 2023?

In the year 2023, Theravance Biopharma distributed 0 USD as dividends.

In which currency does Theravance Biopharma pay out the dividend?

The dividends of Theravance Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Theravance Biopharma

Our stock analysis for Theravance Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Theravance Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.